Carisma Therapeutics Announces Upcoming Conference Participation

Tuesday, March 5, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

PHILADELPHIA, March 5, 2019 /PRNewswire/ -- Carisma Therapeutics Inc., a preclinical-stage biopharmaceutical company

focused on discovering and developing innovative immunotherapies based on chimeric antigen receptor macrophages, today announced that the Company's management will present at three upcoming investor and industry conferences:

  • William Blair
    9th Annual Cancer Immunotherapy Conference – Carisma's management will deliver a scientific presentation on March 20, 2019 at 9:55 am EST. The conference will be held at the Apella, Event Space Alexandria Center in New York, NY;
  • Alliance for Regenerative Medicine Cell & Gene Investment Day – Carisma's management will participate in the conference in New York City and provide a corporate update on March 21, 2019, at 2:15 p.m. EST; and
  • Keystone Symposia on Molecular and Cellular Biology: Innate and Non-Classical Immune Cells in Cancer Immunotherapy – Carisma's management will present in the Cellular Therapies and Biomarkers session on March 28, 2019 at 2:30 p.m. MST. The conference will be held at the Keystone Resort, Keystone, CO.

The Alliance for Regenerative Medicine Cell & Gene Investment Day is filmed and livestreamed from the meeting website at http://arminvestorday.com/webcast/.

About Carisma Therapeutics Inc.

Carisma Therapeutics Inc. is biopharmaceutical company bringing the power of adoptive cellular immunotherapy to solid tumor patients through a differentiated platform using chimeric antigen receptor macrophages. Carisma Therapeutics is headquartered in Philadelphia, PA. For more information, please see the Company's website at https://carismatx.com/.

Media Contact:

Deirdre Purdy for Carisma TherapeuticsDeirdre@0to5.com         914-819-7870

Cision View original content:http://www.prnewswire.com/news-releases/carisma-therapeutics-announces-upcoming-conference-participation-300806800.html

SOURCE Carisma Therapeutics Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store